Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04703543
Other study ID # RS946/17(1974)
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 22, 2017
Est. completion date June 9, 2020

Study information

Verified date January 2021
Source Regina Elena Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the detection rate of local relapse after radical prostatectomy with either PSMA or 64Cu-PET/CTs and whether the delineation of relapsed lesions using both methods can facilitate/change the therapeutic strategy of the radiation oncologist


Description:

PET/TC is a diagnostic tool potentially able to detect, in a single session, both local and distant disease. However, the sensitivity of 18-F-PET/CT in the identification of relapse on the prostatic bed, varies greatly and depends on the value of PSA with which the examination is carried out, the size of the relapse in the lodge, the acquisition protocol and it is limited by the physiological hyperaccumulation of the tracer in the bladder. The sensitivity of 18F-Choline PET/TC in our hands is significantly higher than the one that is generally reported in the literature (76% with PSA values >1 ng/ml after radical prostatectomy), but still lower than the one of mpMR. PET/CT with 64Cu exceeds the limits of 18F-choline PET/TC in the study of the prostatic bed, as the tracer used (64Cu) is not excreted by urinary route and therefore does not accumulate in the bladder. This study has the following objectives: Primary objective: - To evaluate the detection rate of both 64Cu-PET/CT and PSMA-PET/CT of relapses in patients undergoing radical prostatectomy and subsequent biochemical recurrence; Secondary objectives are: - to assess any change in radiation therapy strategy in terms of lesion delineation and dose distribution at planning. - to evaluate the performance of both methods (mpMR and PSMA/64Cu-PET/CT) in assessing the response to radiotherapy with or without androgen deprivation


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date June 9, 2020
Est. primary completion date June 9, 2020
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 90 Years
Eligibility Criteria: Inclusion Criteria: - Localized prostate adenocarcinoma (M0), any PSA value, any Gleason Score - Previous radical surgery with subsequent undetectable PSA (<0.2 ng/ml) - Biochemical recurrence (two consecutive PSA values of at least 0.2 ng/ml) - M0 to 18F-choline PET/TC - Local relapse at mpMR - Age>18 years - Performance Status 0-1 according to ECOG - Informed written consent Exclusion Criteria: - Detectable PSA after surgery - Secondary bone lesions from prostate cancer or M1 - Hormone therapy started before staging examinations - Previous pelvic radiotherapy - Crohn's disease or ulcerative colitis (active phase) - Psychiatric diseases - Contraindication to MRI (metal prostheses, pacemakers, claustrophobia, etc.) - Presence of coxo-femoral implants

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Pilot evaluation study on use PSMA and Cu-PET/CT
This study aims at assessing the detection rate of both PSMA and Cu-PET/CT on tissue relapse, study whether this method is equivalent to mpMR

Locations

Country Name City State
Italy Regina Elena National Cancer Institute Rome

Sponsors (1)

Lead Sponsor Collaborator
Regina Elena Cancer Institute

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary To calculate the detection rate of PSMA and Cu-PET/CT of relapses in patients undergoing radical prostatectomy and subsequent biochemical recurrence Ratio between positive PSMA and Cu-PET/CT patients and the total of enrolled patients (positive MRI) 60 months
See also
  Status Clinical Trial Phase
Completed NCT00970203 - Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer Phase 2
Completed NCT01400555 - A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase 1
Terminated NCT03685591 - PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors Phase 1
Completed NCT00643617 - CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry N/A
Recruiting NCT01581749 - Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer Phase 4
Completed NCT01424930 - A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Completed NCT01228760 - A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer Phase 1
Completed NCT00544440 - An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma Phase 2
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Suspended NCT02759744 - Fusion Guided Focal Laser Ablation of Prostate Cancer N/A
Completed NCT00474383 - An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy Phase 2
Completed NCT01284920 - A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients Phase 1/Phase 2
Completed NCT02319239 - Prostate Cancer Stereotactic Radiotherapy N/A
Completed NCT00910754 - A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 1
Completed NCT00972309 - A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer Phase 1
Terminated NCT03531827 - Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment Phase 2
Completed NCT00167648 - Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer Phase 2
Not yet recruiting NCT05577689 - Novel Therapy Target in Metastatic Prostate Cancer
Enrolling by invitation NCT03173924 - 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer Phase 2
Completed NCT01477749 - Sipuleucel-T Manufacturing Demonstration Study Phase 2